Lipoglycopeptide Antibacterial Drug Class List

Drugs in Drug Class: Lipoglycopeptide Antibacterial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No				Y
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009		RX	Yes	Yes				Y
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes			Y
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes

Last updated: June 15, 2026

Lipoglycopeptide Antibacterial Market Dynamics and Patent Landscape: What’s Covered, When It Expires, and Where Generics/Biosimilars Face Risk

Lipoglycopeptide antibacterial drugs are concentrated in a small set of brands and mechanisms: telavancin (VAC “teli-”), oritavancin (LIV “ori-”), and dalbavancin (DAL “dal-”). Patent protection is dominated by (1) composition-of-matter and crystalline/polymorph coverage for each active ingredient, (2) formulation and dosage-form patents for long-acting regimens, and (3) method-of-use and dosing regimen patents that track label dosing schedules (often once-per-day or single-infusion platforms). Market dynamics are shaped by hospital mix (skin/soft tissue infections vs. hospital-acquired bacterial pneumonia), antimicrobial stewardship pressure, and payer preference for long-acting single-dose or two-dose schedules that reduce administration and IV access burden.

Across the class, the practical exclusivity picture is that older entrants are largely beyond primary exclusivity, while newer lifecycle patents can still delay specific generic routes such as alternate polymorphs, alternative reconstitutions, or specific dosing regimens. Competitive pressure tends to cluster around PBPK/pharmacokinetic defensibility, infusion center economics, and stewardship outcomes, which are often supported in the patent record through dosing studies and formulation stability.

Which lipoglycopeptide antibacterial drugs drive the market today?

Featured snippet answer: The lipoglycopeptide antibacterial market is led by dalbavancin and oritavancin in outpatient and short-stay hospital workflows, with telavancin historically important in inpatient settings but facing heavier competitive pressure from broader-spectrum alternatives and guideline shifts.

What infections and settings define demand?

• Acute bacterial skin and skin structure infections (ABSSSI) are a primary demand driver for dalbavancin and oritavancin.
• Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are key label areas relevant to telavancin.
• Outpatient infusion avoidance matters for reimbursement and length-of-stay reduction, which increases the value of long-acting regimens for dalbavancin and oritavancin.

How payer and hospital incentives shape prescribing?

• Long-acting regimens can reduce infusion visits and nursing time.
• Hospitals weigh drug acquisition cost against IV chair time, pharmacy compounding labor, and length-of-stay metrics.

Competitive adjacency that affects lipoglycopeptide share

Lipoglycopeptides compete indirectly with:

• Other MRSA-active agents (e.g., vancomycin alternatives)
• Oxazolidinones and lipopeptides in some stewardship pathways
• Newer cephalosporins and beta-lactam combinations depending on resistance patterns

Geographic and procurement realities

• Bulk purchasing and group purchasing organization (GPO) contracts can dominate formulary placement.
• Local stewardship committees influence antibiotic selection based on antibiogram and infection control goals.

What patents protect telavancin (lipoglycopeptide) antibacterial formulations and dosing?

Featured snippet answer: Telavancin’s core IP focuses on composition-of-matter for telavancin, plus salts/crystalline forms, and formulation/dosing regimens that support inpatient labeling (including HABP/VABP dosing concepts).

Patent estate structure for telavancin

• Composition-of-matter: telavancin as an active compound.
• Polymorph/crystalline form claims: stability, manufacturability, and solubility behavior.
• Formulation claims: reconstitution and IV infusion compatibility.
• Method-of-use: specific dosing intervals consistent with label-like regimens.

Where generic risk typically concentrates

Generic entry is most vulnerable when challengers can:

• Submit an ANDA with a showing that does not require infringement of telavancin’s specific crystalline/polymorph claims; and
• Avoid claims tied to formulation attributes that are essential to reconstitution, stability, or infusion behavior.

What legal posture tends to matter

For telavancin-like products, the highest barrier is usually not “generic versus brand” per se. It is whether:

• The generic’s solid-state form is captured by crystalline/polymorph patent claims; and
• Formulation parameters map to formulation method claims that remain in force.

What patents protect oritavancin (long-acting lipoglycopeptide) regimens and formulations?

Featured snippet answer: Oritavancin’s IP is typically anchored in telavancin-like active-ingredient compound coverage, then expands into long-acting formulation and regimen patents aligned with its ABSSSI and related label dosing schedules.

Patent estate structure for oritavancin

• Active compound and chemical intermediates.
• Salt/crystal/polymorph strategies to preserve shelf-life and reconstitution stability.
• Dosage-form patents capturing:
  • Amounts-per-vial,
  • Buffering/reconstitution behavior,
  • Administration compatibility.

Why long-acting regimens create patent leverage

Long-acting regimens give rise to method-of-use and regimen claims tied to:

• Total dose and interval structure
• Patient population and infection endpoints consistent with pivotal program narratives

How this changes generic entry calculus

Generic challengers often can clear primary compound claims but still face:

• Crystalline form infringement (if the label route depends on a protected form)
• Formulation and reconstitution method infringement (if their product uses protected processing attributes)

What patents protect dalbavancin (long-acting lipoglycopeptide) dosage forms and crystalline forms?

Featured snippet answer: Dalbavancin’s patent landscape typically combines active ingredient coverage with crystalline/polymorph and long-acting formulation patents that protect IV dosage form behavior for its ABSSSI dosing.

Patent estate structure for dalbavancin

• Chemical entity coverage for dalbavancin.
• Solid-state claims tied to manufacturability and stability.
• Formulation claims tied to reconstitution and infusion performance.
• Method-of-use and dosing regimen claims tied to label and pivotal studies.

Where challengers get blocked most often

• Protected polymorph or solid-state form.
• Formulation patents that require specific buffers, concentration ranges, or processing parameters.
• Dosing regimen patents, where “label-aligned” dosing can still land within claim scope depending on jurisdiction and claim language.

How does exclusivity and patent expiration timing shape generic launch risk?

Featured snippet answer: For lipoglycopeptides, generic launch risk is driven by the intersection of:

1. active ingredient composition-of-matter expiration,
2. later-expiring formulation and crystalline/polymorph patents, and
3. any method-of-use/regimen patents that are still enforceable at the time of FDA application and possible Paragraph IV filings.

Practical exclusivity timeline mechanics for small-molecule antibiotics

• Composition-of-matter patents set the “floor” for generic entry dates.
• Lifecycle patents can create “stairs” that delay specific generic formulations even after the main entity patents expire.
• Hatch-Waxman Orange Book listings often determine the Paragraph IV target set.

What matters most to investors and BD teams

• Whether a generic candidate’s solid-state form and formulation method map cleanly to non-infringement positions.
• Whether brand settlement agreements prevent early design-around launches.
• Whether exclusivity in one dosage strength blocks entry of all strengths.

How strong is the patent estate for each lipoglycopeptide? (Comparative view)

Featured snippet answer: The strongest estates typically sit at the intersection of (a) validated crystalline/polymorph claims and (b) formulation and reconstitution method claims that match label administration workflows.

Comparative ranking framework used in transactions

• Depth: number of distinct independent claim families (compound, solid state, formulation, regimen).
• Survivability: likelihood of enduring claim interpretation under typical litigation constructions.
• Design-around cost: whether alternate solid-state forms or alternative reconstitution recipes are commercially feasible without triggering additional regulatory or quality burdens.

High-level implications by drug

• Dalbavancin and oritavancin often have more “formulation and dosing complexity,” which translates to more lifecycle patent coverage around IV performance and outpatient workflow.
• Telavancin has historically been attacked in the market through guideline shifts and competitive alternatives, with patent leverage depending on how much lifecycle coverage remains for specific dosing/formulation presentations.

Which companies are challenging lipoglycopeptide antibacterial patents, and what litigation affects entry?

Featured snippet answer: Patent challenges for lipoglycopeptides generally occur through Paragraph IV ANDA routes for small molecules; litigation effects are measured by:

• which patents are asserted,
• whether a first generic is enjoined,
• whether settlements allow “authorized” or “delayed” launches, and
• whether design-around strategies shift infringement theories.

What litigation outcomes typically do to pricing and supply

• Enjoined launches create temporary price stabilization.
• Settlements can create staged entry and create “generic parity” after the settlement period.

What BD teams track in each case

• Settlement effective dates.
• Carve-outs for specific strengths or package sizes.
• License scope and whether it includes authorized manufacturing sites and fill-finish constraints.

What is the Orange Book status of lipoglycopeptide antibacterials?

Featured snippet answer: Orange Book listings guide the Paragraph IV universe. For this class, Orange Book status usually reflects:

• multiple patent families per drug,
• separate listing for formulations and sometimes methods, and
• active listings that can persist even after the active ingredient earliest expiration.

Orange Book listing patterns to expect

• Multiple listed patents per drug for:
  • active ingredient,
  • intermediate manufacturing,
  • crystalline/polymorphic variants,
  • dosage form and formulation,
  • sometimes method-of-use or process-linked claims tied to labeled administration.

What formulations are protected (crystalline forms, salts, and reconstitution) for lipoglycopeptides?

Featured snippet answer: Patent protection concentrates on the solid-state identity of the drug substance and on the IV formulation and reconstitution behavior that supports stable, on-label administration.

Key formulation/IP buckets

• Crystalline forms and polymorphs
• Salts and solvate forms
• Buffer systems and concentration ranges
• Reconstitution volumes and stability profiles
• Processing methods that yield protected solids

Why “solid state + formulation” drives litigation

Even when the active molecule is known, infringement can hinge on:

• whether the generic drug’s solid-state form is within the claimed definition, and
• whether the formulation method yields an IV product that maps to claim elements.

What patent barriers exist for generic entry into lipoglycopeptides?

Featured snippet answer: The main barriers are:

• non-infringement challenges against solid-state claims (polymorph/crystal),
• formulation and reconstitution method claims,
• and any still-active method-of-use/regimen patents aligned with label dosing schedules.

Generic launch scenarios that affect forecast models

1. Full bypass: generic proves non-infringement or invalidity across all asserted patents.
2. Design-around: generic changes solid-state identity or formulation recipe to avoid claim scope.
3. Settlement-entry: brand settles and generic launches at a later date or with limited scope.

Where risk is highest for a generic entrant

• Failure to control solid-state polymorph during manufacture.
• Stability and performance differences that force a back-to-brand-like formulation, increasing infringement risk.

How does dalbavancin compare with oritavancin in patent and market dynamics?

Featured snippet answer: Both dalbavancin and oritavancin compete primarily through long-acting ABSSSI administration, but their patent leverage tends to cluster around different lifecycle layers, which can change which generic designs are feasible first.

Business dynamics that influence share

• Admin workflow fit: infusion chair logistics, outpatient capability.
• Payer policies that reward reduced visits.
• Net price and contract structure more than list price.

IP dynamics that influence first-to-market generics

• Whether an early challenger can get around crystalline/formulation coverage.
• Whether settlement agreements allow a “first generic” to launch earlier for one drug versus the other.

How does telavancin compare with dalbavancin and oritavancin?

Featured snippet answer: Telavancin’s market role historically skews toward inpatient and pneumonia-linked use, while dalbavancin and oritavancin are more outpatient/short-stay ABSSSI-oriented. The patent posture differs accordingly, with telavancin often carrying a different mix of method-of-use and formulation claims.

Competitive dynamics

• Telavancin faces stronger substitution pressure depending on local pneumonia treatment pathways and guideline adherence.
• Long-acting dalbavancin/oritavancin workflows can create procurement advantages that indirectly blunt competitive uptake.

What regulatory and FDA pathway issues affect generic launches for lipoglycopeptides?

Featured snippet answer: For small-molecule lipoglycopeptides, generic entry typically proceeds via ANDA routes and must satisfy bioequivalence and chemistry, manufacturing, and controls requirements that interact with patent-protected solid-state and formulation characteristics.

Regulatory mechanics that intersect with IP

• ANDA approval requires demonstrating equivalence in:
  • drug substance,
  • formulation and performance,
  • manufacturing controls that maintain solid-state identity.

Bioequivalence and stability constraints

Design-around formulations still must meet stability and performance specs, which can force costly changes that create practical barriers even when legal non-infringement is plausible.

Key Takeaways

• Lipoglycopeptide antibacterials are a narrow class with market power concentrated in long-acting IV regimens for ABSSSI (primarily dalbavancin and oritavancin) and an inpatient pneumonia footprint historically relevant to telavancin.
• The patent landscape is driven less by the basic active ingredient alone and more by crystalline/polymorph and formulation/reconstitution lifecycle layers that map to how drugs are administered in real hospital workflows.
• Generic entry risk concentrates on whether challengers can control solid-state form and avoid formulation method claim elements while still meeting ANDA quality, stability, and bioequivalence requirements.
• Litigation and settlements typically determine the commercial timetable, with scope often split by strength, presentation, and launch timing, not just headline patent expiry.

FAQs

1) Do lipoglycopeptide ANDAs usually face Paragraph IV challenges on compound patents or lifecycle formulation patents?

Lifecycle patents are commonly targeted because solid-state and formulation claims are more likely to remain listed and enforceable at the time of generic filing.

2) What design-around levers are most realistic for lipoglycopeptide generics?

Solid-state identity changes (polymorph/crystal) and formulation recipe/process changes that avoid reconstitution and concentration claim elements.

3) Can a generic avoid infringement by changing the manufacturing process but keeping the same crystalline form?

Only if the crystalline form still falls outside claim scope; many crystalline patents are defined by structural/solid-state characteristics that can be independent of process wording.

4) How do dosing regimen patents affect generic substitution timing?

If method-of-use/regimen claims remain in force, a generic product that is otherwise equivalent can still be blocked or delayed when its use maps to the claimed dosing schedule.

5) What market signals best predict generic entry timelines in this class?

Orange Book listing density at filing time, the number of asserted patents in early Paragraph IV litigation, and settlement terms that specify launch dates and scope by presentation.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (CDER). https://www.accessdata.fda.gov/scripts/cder/daf/
2. Hatch-Waxman Act (21 U.S.C. § 355).
3. FDA. ANDA guidance documents on bioequivalence and CMC expectations. https://www.fda.gov/drugs/administration-approvals-and-lifecycle/abbreviated-new-drug-application-anda